APA (7th ed.) Citation

D, H., NN, F., MN, A., & RA, N. (2022). The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: A Systematic Review and Meta-analysis. Medical archives (Sarajevo, Bosnia and Herzegovina), 76(5), 333. https://doi.org/10.5455/medarh.2022.76.333-342

Chicago Style (17th ed.) Citation

D, Hermansyah, Firsty NN, Alhudawy MN, and Nasution RA. "The Combination of CDK 4/6 Inhibitors Plus Endocrine Treatment Versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive Breast Cancer: A Systematic Review and Meta-analysis." Medical Archives (Sarajevo, Bosnia and Herzegovina) 76, no. 5 (2022): 333. https://doi.org/10.5455/medarh.2022.76.333-342.

MLA (9th ed.) Citation

D, Hermansyah, et al. "The Combination of CDK 4/6 Inhibitors Plus Endocrine Treatment Versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive Breast Cancer: A Systematic Review and Meta-analysis." Medical Archives (Sarajevo, Bosnia and Herzegovina), vol. 76, no. 5, 2022, p. 333, https://doi.org/10.5455/medarh.2022.76.333-342.